Multiple Sclerosis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Multiple Sclerosis Therapeutics Market is segmented by Drug Type (Large-molecule Drugs and Small-molecule Drugs), Route of Administration, and Geography

Market Snapshot

Multiple Sclerosis Therapeutics Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.5 %
Multiple Sclerosis Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The market studied is expected to witness a rapid growth rate in the future, owing to factors, such as the rising prevalence of multiple sclerosis (MS) and the growing focus of companies on pipeline products for MS.

  • Big pharmaceutical companies have been investing heavily in the drug development process and are planning to target as many indications as possible, in order to cater to a large number of customers. Owing to this, the MS market has also been benefiting. For instance, the drugs being developed for multiple sclerosis include the drugs for Relapsing-remitting MS, Secondary progressive MS, Primary progressive MS, and Myelin repair or neuroprotection.
  •  Biogen, a leading player in the market studied has been developing Diroximel fumarate, which is currently in phase III of development; similarly, Novartis has been developing Ofatumumab, which is also in Phase III.
  • Similar to the above-mentioned companies, there have been other pharmaceutical players, such as Pfizer Inc., which have been developing drugs for MS. This indicates that pipeline drugs for MS may boost the studied market's growth in the forecast period.

Scope of the Report

As stated by the National Multiple Sclerosis Society, multiple sclerosis (MS) involves an immune-mediated process, in which an abnormal response of the body’s immune system is directed against the central nervous system (CNS). The MS therapeutics market covers the drugs that are being used for the treatment of this disease or to reduce the complications associated with the same.

By Drug Type
Large-molecule Drugs
Small-molecule Drugs
By Route of Administration
Injectable and Others
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Oral Route of Administration is Expected to Witness Rapid Growth in Future

Classical multiple sclerosis (MS) treatments using first-line injectable drugs, even though they have been widely applied, remain to be a foremost concern in terms of therapeutic adherence and efficacy. Novel oral drugs, recently approved for the treatment of MS, represent significant advances in the therapy. The oral route of administration evidently supports patient satisfaction and increases therapeutic compliance.

If someone is not comfortable with needles, there are oral options for treating MS. Taken daily or twice daily, oral medications require one to maintain a regular dosing schedule. These are the easiest to be self-administered.

The currently available oral multiple sclerosis drugs include Aubagio (teriflunomide), Gilenya (fingolimod), and Tecfidera (dimethyl fumarate).

In March 2019, the US Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Multiple Sclerosis Therapeutics Market Key Trends

North America to Dominate the Market

The market for multiple sclerosis therapeutics is expected to show high growth in the North America region, which is majorly attributed to the presence of key players and the rising prevalence of the disease in this region. The United States is the major market for companies, such as Biogen, Novartis AG, and Sanofi SA, among others. Therefore, these companies have been focusing more on establishing their new drugs in this market studied, which ultimately has been contributing to the growth of this region.

Furthermore, as per the National Multiple Sclerosis Society, Canada is a country with the highest prevalence of MS in the world (291 per 100,000). In the case of the United States, the National MS Society estimated that there are around 1 million people in the country living with MS.

Hence, due to the high prevalence and presence of the key players, North America is expected to dominate the market studied.

Multiple Sclerosis Therapeutics Market Growth Rate

Competitive Landscape

The market for MS therapeutics is consolidated, as there are few players in this market. These companies are the big pharmaceutical companies that have been focusing on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, it is believed that more companies may enter the market studied in the future, and the competition may increase.

Recent Developments


Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Raised Cases of Multiple Sclerosis across the World

      2. 4.2.2 Growing Focus of Companies on Pipeline Products for MS

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with the Medication

      2. 4.3.2 High Cost of the Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Large-molecule Drugs

      2. 5.1.2 Small-molecule Drugs

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Injectable and Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Teva Pharmaceuticals

      2. 6.1.2 Novartis AG

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Biogen Idec

      5. 6.1.5 Bayer AG

      6. 6.1.6 Sanofi SA

      7. 6.1.7 Mylan NV

      8. 6.1.8 Merck KGaA (Serono)

      9. 6.1.9 F. Hoffmann-La Roche AG

      10. 6.1.10 Acorda Therapeutics Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Multiple Sclerosis Therapeutics Market market is studied from 2018 - 2026.

The Multiple Sclerosis Therapeutics Market is growing at a CAGR of 6.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Biogen Inc., Novartis AG, Merck KGaA, Sanofi S. A., Acorda Therapeutics, Inc. are the major companies operating in Multiple Sclerosis Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!